Restylane and Cetaphil
Regional launch across all seven Central American markets: congresses, in-clinic activation, physician programs. Both went from absent to present in every market.
Opened the door for the rest of the portfolio.
Regional launch across all seven Central American markets: congresses, in-clinic activation, physician programs. Both went from absent to present in every market.
Opened the door for the rest of the portfolio.
Ellansé and Silhouette Soft, from good product to reference name in collagen biostimulators, with a regional expert panel that certified and trained physicians.
Share won from established players.
Took a neglected dermatology portfolio.
Back to meaningful share, real revenue and profit.
A launch that arrived with its origin working against it, in a category where the big brands had been entrenched for years.
Started strong and held a position of its own.
Founded and ran a medical-aesthetics company from the ground up. Brought in the exclusive LG Chem license and launched Yvoire and Nabota in a crowded category: positioning, KOL network, clinical-education engine. Nabota came in as the safe, profitable toxin — the first Korean one approved by the FDA.
Competing against Galderma, Merz and Sinclair.
Regional commercial leadership across the U.S., Mexico and Central America — owning P&L, teams and KOL relationships.
From the corporate side and from the owner’s side.
A strategy written by someone who has never had to hit a number is an opinion. I carried the P&L for fifteen years across the U.S., Mexico and Central America, with a team and a budget of my own. I know what moves a business when the result is yours, and I also know what looks great in a deck and changes nothing.
I know my category to the bottom and I work with AI every day: I read a market in days, not months.